Scinai Immunotherapeutics (NASDAQ:SCNI) Issues Quarterly Earnings Results, Beats Estimates By $8.80 EPS

Scinai Immunotherapeutics (NASDAQ:SCNI) posted its earnings results on Monday. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($8.50) by $8.80, FiscalAI reports. The firm had revenue of $1.86 million during the quarter, compared to analyst estimates of $0.49 million.

Scinai Immunotherapeutics Stock Performance

SCNI stock traded up $0.05 during midday trading on Tuesday, hitting $0.51. The company’s stock had a trading volume of 3,895 shares, compared to its average volume of 749,436. Scinai Immunotherapeutics has a 1 year low of $0.39 and a 1 year high of $13.00. The stock’s 50-day moving average price is $1.24 and its 200 day moving average price is $4.23. The stock has a market cap of $689,850.00, a price-to-earnings ratio of -0.01 and a beta of 2.27. The company has a quick ratio of 1.35, a current ratio of 1.56 and a debt-to-equity ratio of 0.05.

Shares of Scinai Immunotherapeutics are going to reverse split before the market opens on Thursday, November 19th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, November 18th.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Scinai Immunotherapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, October 21st. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Scinai Immunotherapeutics presently has a consensus rating of “Sell”.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects.

Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.